The CC chemokine RANTES as a potential contributor to breast cancer progression

  • E Azenshtein
  • G Luboshits
  • S Shina
  • E Neumark
  • N Vigler
  • S Chaitchik
  • I Keydar
  • A Ben-Baruch
Meeting abstract
  • 3k Downloads

Keywords

Breast Cancer Breast Cancer Patient Breast Tumor Breast Carcinoma Breast Cancer Progression 

In breast carcinoma, high levels of tumor-associated macrophages are correlated with lymph node metastases and clinical aggressiveness. Potential candidates that may support the recruitment of monocytes from the circulation into breast tumors are the members of the CC subfamily of chemokines. In the present study we evaluated the expression of the CC chemokine RANTES in sections of breast cancer patients diagnosed in different stages of disease. Our results indicate that high incidence and intensity of RANTES expression were directly correlated with a more advanced disease, suggesting that the chemokine may be involved in breast cancer progression.

Analyses performed by using the T47D and MCF-7 human breast adenocarcinoma cells indicated that RANTES expression is tightly regulated by cytokines. Furthermore, the results of our study indicate that T47D-derived RANTES partially contributes to monocyte migration, and suggest that in vivo this chemokine may be involved in inducing monocyte infiltration to breast tumor sites. In the present study we further characterized the paracrine and autocrine mechanisms by which RANTES may support breast cancer progression. The results suggest that RANTES may be involved in a complex process, in which a crosstalk between infiltrating monocytes and the tumor cells may affect tumor progression.

Copyright information

© BioMed Central Ltd 2001

Authors and Affiliations

  • E Azenshtein
    • 1
  • G Luboshits
    • 1
  • S Shina
    • 1
  • E Neumark
    • 1
  • N Vigler
    • 2
  • S Chaitchik
    • 3
  • I Keydar
    • 1
  • A Ben-Baruch
    • 1
  1. 1.Department of Cell Research and Immunology, George S Wise Faculty of Life SciencesTel-Aviv UniversityTel-AvivIsrael
  2. 2.Department of OncologyTel-Aviv Sourasky Medical CenterTel-AvivIsrael
  3. 3.Department of Oncology, Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations